U.S. Stock Market Update: Windtree Therapeutics down 7.13%

U.S. Stock Market Midday Update

Windtree Therapeutics, down 7.13%, with increased trading volume. Based on recent key news:

1. On July 27, Kraken announced a partnership with Windtree to provide strategic support for digital assets. Although this move aims to strengthen the company, the market reacted negatively, leading to a 7.13% drop in stock price.

2. On July 27, retail investors showed a surge in interest in small-cap stocks, resulting in increased market volatility, affecting Windtree.

3. On July 28, uncertainty in the real estate market intensified, impacting investor sentiment and further dragging down Windtree's stock price.

Top Stocks by Trading Volume in the Industry

Celcuity surged 178.36%, with a trading volume of $1.047 billion. Based on recent important news:

1. On July 28, Celcuity announced that its three-drug combination therapy outperformed AstraZeneca's treatment in breast cancer trials, significantly improving progression-free survival, leading to a 114% increase in stock price.

2. On July 28, Celcuity plans to submit a new drug application to the U.S. FDA in the fourth quarter of 2025, with a positive market reaction.

3. On July 29, HC Wainwright & Co. raised Celcuity's target price from $27 to $50, further driving up the stock price.

Forte Biosciences, down 1.23%, with a trading volume of $395 million. Based on recent key news:

1. On July 28, WuXi AppTec announced its interim results, with shareholder profit rising 95.46% year-on-year and an upward revision of its full-year operating outlook, expecting revenue growth to be adjusted to 13% to 17%. This news boosted market confidence in the industry as a whole, but Forte Biosciences failed to benefit, with a 1.23% drop in stock price.

2. On July 27, the U.S. stock market experienced a "retail investor riot," with a surge in trading volume for small-cap stocks with a high short interest, leading to increased market volatility. Forte Biosciences, as one of the small-cap stocks, was affected, resulting in a drop in stock price.

3. On July 28, Vertex Pharmaceuticals failed to make the list of top stocks recommended by analysts, despite still having a "moderate buy" rating. This news may have affected investor confidence in the biopharmaceutical industry, indirectly leading to a decline in Forte Biosciences' stock price.

Gilead Sciences, down 2.81%, with increased trading volume. Based on recent important news:

1. On July 26, the U.S. FDA approved Gilead's Yeztugo as a new PrEP option. This news was expected to boost the stock price, but the market reaction was below expectations, resulting in a 2.81% drop in stock price.

2. On July 28, analysts pointed out that Gilead was not included in the recommended buy list, undermining market confidence

3. On July 27, the market was skeptical about Yeztugo's long-term growth potential, leading to pressure on its stock price.

Stocks ranked among the top in industry market capitalization

AbbVie fell 0.92%, with increased trading volume. Based on recent important news:

1. On July 28, AbbVie's cancer drug Rova-T failed in clinical trials, and the company turned to Skyrizi and Rinvoq to drive growth. Although these drugs performed better than expected, market confidence in their future growth was affected, resulting in a decline in stock price.

2. On July 26, market analysis showed that although AbbVie was rated as "moderate buy," top analysts believed there were five stocks more worthy of purchase, which could lead to a decline in investor confidence.

3. On July 27, retail trading volume surged, increasing market volatility, which may have an indirect impact on AbbVie's stock price